Good News | Hycells Bio Completes Tens of Millions in Pre-A Round Funding
Release Date:
2026-02-09 16:52
Recently, Wuxi Hycells Biotechnology Co., Ltd.—a biotech company specializing in primary cell technologies and innovative solutions—announced the completion of a Pre-A round of financing totaling several tens of millions of RMB. This round was co-led by Guolian Jintou Zhiyuan, the core market-oriented fund investment platform under Wuxi Guolian Group, together with the Wuxi Xidong Industrial Investment Center. The funds will be primarily used to drive the iterative upgrade of the company’s GMP-compliant products, accelerate its global business expansion, and further strengthen its integrated product-and-service solutions centered on primary cells.
Hycells Biotechnology is a biotech company specializing in primary cell technologies and innovative solutions. Headquartered in the Wuxi Precision Medicine Industrial Park, the company operates dual hubs in Wuxi and Shanghai: the Wuxi center focuses on product R&D, manufacturing, and commercialization, while the Shanghai center concentrates on primary cell preparation and technical services. Hycells is committed to providing domestically developed, independent tools and technological support for biopharmaceutical R&D and manufacturing. Leveraging its proprietary R&D platform, the company has established an integrated service system encompassing “sample services–specialized products–technical service platform,” with a core business portfolio centered on primary immune cells, stem cells, and hepatocytes. In addition, it has expanded into HiXpan® cell culture products, HiMag sorting reagent kits, CAR-positive rate detection reagents, ELISpot assay kits, and other diagnostic products. Furthermore, the company has broadened its technical service offerings to include in vitro efficacy evaluation, drug immunogenicity assessment, and drug hematotoxicity testing—providing precise coverage of critical stages in biopharmaceutical R&D and manufacturing and delivering end-to-end, one-stop solutions to clients. Notably, several of its products and services have broken long-standing foreign monopolies, achieving domestic innovation and even surpassing international standards.
Following this round of financing, Hycells Bio is poised to enter a new phase of rapid growth. The company will continue to refine its product portfolio, enhance the quality and production capacity of GMP-grade products, and strengthen its core competitive advantages in the domestic substitution space. At the same time, it will accelerate the global commercialization of primary cells, along with their associated reagents, consumables, and technical services, and further deepen its international market presence. Currently, both the global and Chinese biopharmaceutical industries are experiencing robust growth, driven by technological innovation, supportive policies, and strong market demand. A representative from Guolian Jintou Zhiyuan stated that the firm will continue to provide sustained support for Hycells Bio’s investments in R&D, capacity expansion, and market development, helping the company expedite the localization and domestic substitution of its products and services and contributing to the independent innovation and high-quality development of China’s biopharmaceutical industry.
About Hycells Biology
Wuxi Hycells Biotechnology Co., Ltd. is an innovative biotechnology company focused on primary cells and related reagents and technical services. With a long-standing commitment to the fields of cell and gene therapy (CGT) and large-molecule therapeutics, the company is dedicated to providing customers with end-to-end, one-stop solutions for primary cell products—covering research and development, manufacturing, sales, and technical services.
The company’s core strategy is to build an integrated, closed-loop business model encompassing “biological samples–technical services–products.” Leveraging high-standard sample resources, professional and compliant services, and a distinctive product portfolio, the company provides end-to-end support to clients throughout the entire value chain—from R&D to commercialization—and aspires to become a trusted, core partner across the global biopharmaceutical industry. To date, the company has established an R&D and GMP manufacturing facility spanning more than 3,000 square meters. Its wholly owned subsidiary, Shanghai Hycells Biotechnology Co., Ltd., has obtained GB/T 19001-2016/ISO 9001:2015 quality management system certification and has been recognized as a “Shanghai High-Tech Enterprise” and a “Shanghai Specialized, Sophisticated, Distinctive, and Innovative SME.”
The company has consistently upheld the core values of “talent as the foundation, quality first, and innovation as the cornerstone,” steadfastly leveraging technology-driven innovation to set new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
About Guolian JinTou ZhiYuan
Guolian JinTou Zhiyuan is the core entity responsible for the market-oriented reform of Wuxi Innovation Investment Group. Operating on a fully market-based model and benchmarking against world-class venture capital firms, it has built a highly professional and disciplined team. Leveraging the Group’s deep, long-term presence across the Yangtze River Delta region, the firm focuses on technology-driven innovation opportunities in China’s strategic emerging industries, serves outstanding startups and entrepreneurs, and continuously strengthens its brand influence. In the short term, it aims to elevate the company’s performance, assets under management, and industry standing to the forefront of China’s venture capital sector.
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board